NZ712159A - Antiemetic extended release solid dosage forms - Google Patents

Antiemetic extended release solid dosage forms

Info

Publication number
NZ712159A
NZ712159A NZ712159A NZ71215914A NZ712159A NZ 712159 A NZ712159 A NZ 712159A NZ 712159 A NZ712159 A NZ 712159A NZ 71215914 A NZ71215914 A NZ 71215914A NZ 712159 A NZ712159 A NZ 712159A
Authority
NZ
New Zealand
Prior art keywords
amount
antiemetic
drug
dosage forms
solid dosage
Prior art date
Application number
NZ712159A
Other languages
English (en)
Inventor
Reza Fathi
Gilead Raday
Original Assignee
Redhill Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51528070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ712159(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Redhill Biopharma Ltd filed Critical Redhill Biopharma Ltd
Publication of NZ712159A publication Critical patent/NZ712159A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ712159A 2013-03-14 2014-03-14 Antiemetic extended release solid dosage forms NZ712159A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361782395P 2013-03-14 2013-03-14
PCT/IB2014/001633 WO2014181195A2 (en) 2013-03-14 2014-03-14 Antiemetic extended release solid dosage forms

Publications (1)

Publication Number Publication Date
NZ712159A true NZ712159A (en) 2019-12-20

Family

ID=51528070

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ712159A NZ712159A (en) 2013-03-14 2014-03-14 Antiemetic extended release solid dosage forms

Country Status (19)

Country Link
US (5) US9636305B2 (enExample)
EP (1) EP2983664B1 (enExample)
JP (1) JP6282676B2 (enExample)
KR (1) KR102270521B1 (enExample)
CN (2) CN105530935A (enExample)
AU (1) AU2014264342B2 (enExample)
BR (1) BR112015022398B1 (enExample)
CA (1) CA2905553C (enExample)
CL (1) CL2015002666A1 (enExample)
ES (1) ES2946985T3 (enExample)
HK (1) HK1223012A1 (enExample)
IL (1) IL241580B (enExample)
MX (1) MX378261B (enExample)
NZ (1) NZ712159A (enExample)
PH (1) PH12015502093B1 (enExample)
RU (1) RU2679448C2 (enExample)
SG (1) SG11201507450TA (enExample)
WO (2) WO2014181195A2 (enExample)
ZA (1) ZA201506961B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9636305B2 (en) 2013-03-14 2017-05-02 Redhill Biopharma Ltd. Antiemetic extended release solid dosage forms
EP3116500B1 (en) 2014-03-11 2023-09-13 RedHill Biopharma Ltd. Ondansetron extended release solid dosage forms for treating diarrhea predominant irritable bowel syndrome
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
WO2020080875A1 (ko) * 2018-10-19 2020-04-23 주식회사 삼양바이오팜 아프레피탄트의 경구용 조성물
US11969416B1 (en) 2022-11-03 2024-04-30 Lumos Pharma, Inc. Compactable oral formulations of ibutamoren

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4720353A (en) * 1987-04-14 1988-01-19 Richardson-Vicks Inc. Stable pharmaceutical w/o emulsion composition
US6090411A (en) 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
US6733789B1 (en) * 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
DE60019334T2 (de) 1999-12-09 2005-09-08 Alza Corp., Mountain View Antivirale arznei
WO2003024427A1 (en) 1999-12-20 2003-03-27 Temple University Of The Commonwealth System Of Higher Education Tableted oral extended release dosage form
US6936275B2 (en) 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US20020172712A1 (en) * 2001-03-19 2002-11-21 Alan Drizen Antiemetic, anti-motion sustained release drug delivery system
GB0119012D0 (en) 2001-08-03 2001-09-26 Strakan Group Plc Transdermal delivery of drugs
GB0129489D0 (en) * 2001-12-10 2002-01-30 Quadrant Healthcare Uk Ltd Sustained-release compositions
US20050131045A1 (en) 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
US7704527B2 (en) 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
BRPI0406748A (pt) 2003-01-13 2005-12-20 Dynogen Pharmaceuticals Inc Método de tratamento de náusea, vÈmito e ânsia de vÈmito ou qualquer combinação destes em um paciente que necessite do mesmo e composição farmacêutica
KR101052705B1 (ko) 2003-11-14 2011-08-01 센주 세이야꾸 가부시키가이샤 아미노글리코시드계 항생물질 및 브롬페낙을 함유하는수용액 제제
CA2579767A1 (en) * 2004-04-30 2005-11-10 Astellas Pharma Inc. Oral pharmaceutical composition in timed-release particle form and fast-disintegrating tablets containing this composition
CN101132777A (zh) * 2004-12-20 2008-02-27 科利吉姆制药公司 用于睡眠障碍的药物组合物
DE602006018529D1 (de) * 2005-12-29 2011-01-05 Osmotica Kereskedelmi Es Szolgaltato Kft Mehrschichtige tablette mit dreifacher freisetzungskombination
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20080004260A1 (en) 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
KR101556797B1 (ko) * 2006-08-18 2015-10-01 에보니크 룀 게엠베하 양호한 수용해도를 가지는 활성 성분을 위한 활성 성분 전달이 제어되는 제약 조성물
CN100584319C (zh) 2006-10-16 2010-01-27 北京科信必成医药科技发展有限公司 群孔释放渗透泵控释片及其制备方法
CN101528205A (zh) 2006-10-25 2009-09-09 麦克内尔-Ppc股份有限公司 布洛芬组合物
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
JP2010514679A (ja) * 2006-12-22 2010-05-06 スリーエム イノベイティブ プロパティズ カンパニー 制御放出組成物及び方法
WO2009118763A1 (en) 2008-03-28 2009-10-01 Panacea Biotec Limited Multilayered pharmaceutical compositions and processes thereof
US20100196291A1 (en) * 2009-01-30 2010-08-05 Laurence Halimi Personal care sunscreen compositions having reduced eye irritation
EP2403487A2 (en) * 2009-03-04 2012-01-11 Fdc Limited Oral controlled release dosage forms for water soluble drugs
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
RU2427389C2 (ru) * 2009-10-09 2011-08-27 Александр Владимирович Диковский Фармацевтическая композиция для профилактики и лечения инфекционных и неинфекционных диарей
WO2011066289A1 (en) * 2009-11-30 2011-06-03 Eurand, Inc. Ondansetron orally disintegrating tablet compositions for prevention of nausea and vomiting
EP2515882A2 (en) * 2009-12-22 2012-10-31 Abbot Healthcare Private Limited Controlled release pharmaceutical composition
AU2010343147A1 (en) 2009-12-28 2012-07-19 Monosol Rx, Llc Orally administrable film dosage forms containing ondansetron
WO2012028922A2 (en) 2010-08-30 2012-03-08 Lupin Limited Controlled release pharmaceutical compositions of milnacipran
US20120128730A1 (en) * 2010-11-23 2012-05-24 Nipun Davar Compositions and methods for once-daily treatment of obsessive compulsive disorder with ondansetron
US9636305B2 (en) 2013-03-14 2017-05-02 Redhill Biopharma Ltd. Antiemetic extended release solid dosage forms

Also Published As

Publication number Publication date
CN112274489A (zh) 2021-01-29
ZA201506961B (en) 2017-03-29
ES2946985T3 (es) 2023-07-31
SG11201507450TA (en) 2015-10-29
US20140271851A1 (en) 2014-09-18
US20170189340A1 (en) 2017-07-06
CL2015002666A1 (es) 2017-02-17
HK1223012A1 (zh) 2017-07-21
JP6282676B2 (ja) 2018-02-21
MX2015012970A (es) 2016-04-11
RU2679448C2 (ru) 2019-02-11
US9636305B2 (en) 2017-05-02
BR112015022398A8 (pt) 2019-11-26
CN105530935A (zh) 2016-04-27
US20200330392A1 (en) 2020-10-22
PH12015502093A1 (en) 2016-01-18
KR20150127253A (ko) 2015-11-16
AU2014264342B2 (en) 2017-05-18
RU2015143993A (ru) 2017-04-20
KR102270521B1 (ko) 2021-06-30
MX378261B (es) 2025-03-10
BR112015022398B1 (pt) 2022-01-11
RU2015143993A3 (enExample) 2018-03-21
WO2014184662A3 (en) 2015-04-02
PH12015502093B1 (en) 2018-09-26
US20140271887A1 (en) 2014-09-18
WO2014181195A3 (en) 2015-12-17
WO2014181195A2 (en) 2014-11-13
US20180028452A1 (en) 2018-02-01
JP2016512493A (ja) 2016-04-28
CA2905553C (en) 2021-04-06
EP2983664B1 (en) 2023-04-19
CA2905553A1 (en) 2014-11-13
WO2014184662A2 (en) 2014-11-20
IL241580B (en) 2020-08-31
EP2983664A4 (en) 2017-01-04
AU2014264342A1 (en) 2015-10-01
EP2983664A2 (en) 2016-02-17
BR112015022398A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
PH12014501446B1 (en) Solid nicotine-comprising dosage form with reduced organoleptic disturbance
PH12015501756A1 (en) Tamper resistant pharmaceutical formulations
PH12015502093A1 (en) Antiemetic extended release solid dosage forms
JP2015523407A5 (enExample)
UY31698A (es) Preparacion solida de desintegracion oral
UA117685C2 (uk) Складена композиція для перорального введення, яка містить езетиміб та розувастатин
PH12015501015A1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
UA115811C2 (uk) Стабільний розчин об'єднаних баклофену, сорбіту і налтрексону для перорального застосування
MX2012013021A (es) Formulaciones resistentes a alcohol.
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
PH12020550806A1 (en) Core tablet composite preparation comprising mosapride and rabeprazole
WO2015065546A3 (en) Abuse-deterrent dosage forms
IN2014DN03429A (enExample)
BR112013000300A2 (pt) comprimido que se desintegra intraoralmente
MX385881B (es) Forma de dosificacion de alivio prolongado
TR201001417A1 (tr) Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu
MX359887B (es) Composicion masticable para administracion oral y proceso para preparar la misma.
PH12016501756B1 (en) Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
PH12016500693B1 (en) Slow-release solid oral compositions
ECSP16005208A (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
CY1123933T1 (el) Σκευασματα παρατεταμενης αποδεσμευσης λοραζεπαμης
MX2012013023A (es) Formas de dosificacion de liberacion prolongada resistentes ala alcohol y que comprenden venlafaxina.
MX2015013470A (es) Microcapsulas de piperaquina y composiciones que las contienen.
BR112014026040A2 (pt) tablete de liberação sustentada que contém levodropropizina e método para preparar o mesmo
CL2016002655A1 (es) Composición farmacéutica para el tratamiento de alopatías relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2022 BY CPA GLOBAL

Effective date: 20210128

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2023 BY CPA GLOBAL

Effective date: 20220128

LAPS Patent lapsed